Home›Stock Screener›Eris Lifesciences›Intrinsic Value

Eris Lifesciences Intrinsic Value

Eris Lifesciences intrinsic value. Eris Lifesciences (ERIS) median intrinsic value is ₹2658.00 from 10 valuation models (range ₹399–₹3323), vs current price ₹1329.00 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse ERIS financial statements for revenue, profit, balance sheet and cash flow data.

Market Price (CMP)
₹1329.00
Primary Intrinsic Value
₹1166.88
Market Cap
₹1861 Cr
+100.0% Upside
Median Value
₹2658.00
Value Range
₹399 - ₹3323
Assessment
Trading Below Calculated Value
Safety Margin
50.0%

ERIS Valuation Methods Summary — DCF, Graham Number & P/E

Eris Lifesciences intrinsic value across 10 models vs current price ₹1329.00 — upside/downside and value range per method. Analyse Eris Lifesciences shareholding analysis to track promoter, FII and institutional holdings.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹1166.88 ₹933.50 - ₹1400.26 -12.2% EPS: ₹53.04, Sector P/E: 22x
Book Value Method asset ₹3322.50 ₹2990.25 - ₹3654.75 +150.0% Book Value/Share: ₹2782.86, P/B: 2.0x
Revenue Multiple Method revenue ₹2658.00 ₹2392.20 - ₹2923.80 +100.0% Revenue/Share: ₹2551.43, P/S: 2.0x
EBITDA Multiple Method earnings ₹2658.00 ₹2392.20 - ₹2923.80 +100.0% EBITDA: ₹1092.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹3322.50 ₹2658.00 - ₹3987.00 +150.0% CF Growth: 9.2%, Discount: 15%
PEG Ratio Method growth ₹398.70 ₹358.83 - ₹438.57 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹819.47 ₹737.52 - ₹901.42 -38.3% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹2658.00 ₹2392.20 - ₹2923.80 +100.0% ROE: 19.2%, P/E Multiple: 14x
Graham Defensive Method conservative ₹1822.38 ₹1640.14 - ₹2004.62 +37.1% EPS: ₹53.04, BVPS: ₹2782.86
Dividend Yield Method dividend ₹398.70 ₹358.83 - ₹438.57 -70.0% DPS: ₹7.21, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

ERIS Intrinsic Value vs Market Price — All Valuation Models

Eris Lifesciences fair value range ₹399–₹3323 vs current market price ₹1329.00 across 10 valuation models. For current market price and key ratios, visit Eris Lifesciences share price today.

ERIS Intrinsic Value Analysis — Undervalued or Overvalued?

Eris Lifesciences median intrinsic value ₹2658.00, current price ₹1329.00 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.

What is the intrinsic value of ERIS?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Eris Lifesciences (ERIS) is ₹2658.00 (median value). With the current market price of ₹1329.00, this represents a +100.0% variance from our estimated fair value.

The valuation range spans from ₹398.70 to ₹3322.50, indicating ₹398.70 - ₹3322.50.

Is ERIS undervalued or overvalued?

Based on our multi-method analysis, Eris Lifesciences (ERIS) appears to be trading below calculated value by approximately 100.0%.

ERIS Financial Health — Key Ratios vs Industry Benchmarks

Eris Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 19.2% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 30.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 0.48x Industry Standard: 1.0x+ Below 0.5x Measures asset utilization efficiency

ERIS Cash Flow Quality — Operating & Free Cash Flow

Eris Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹538 Cr ₹353 Cr Positive Free Cash Flow 8/10
March 2025 ₹1,065 Cr ₹1,026 Cr Positive Free Cash Flow 8/10
March 2024 ₹486 Cr ₹-428 Cr Positive Operating Cash Flow 6/10
March 2023 ₹292 Cr ₹-196 Cr Positive Operating Cash Flow 6/10
March 2022 ₹378 Cr ₹218 Cr Positive Free Cash Flow 8/10